OncoCyte (NASDAQ:OCX) PT Raised to $4.25 at Needham & Company LLC

OncoCyte (NASDAQ:OCX) had its price objective raised by Needham & Company LLC from $3.60 to $4.25 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the stock. Benchmark reaffirmed a speculative buy rating and issued a $5.00 price target on shares of OncoCyte in a research report on Monday, April 15th. StockNews.com began coverage on OncoCyte in a report on Wednesday. They set a sell rating for the company. Finally, Stephens reiterated an equal weight rating and issued a $4.00 price target on shares of OncoCyte in a report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Hold and an average price target of $4.06.

OncoCyte Stock Performance

OCX stock opened at $2.46 on Wednesday. OncoCyte has a 1-year low of $2.08 and a 1-year high of $6.20. The business has a 50-day moving average price of $2.92 and a 200 day moving average price of $3.04.

Insider Activity at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were purchased at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the purchase, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Andrew Arno purchased 33,898 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the purchase, the director now owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders bought 2,457,288 shares of company stock valued at $7,176,400 over the last 90 days. Insiders own 1.94% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.